Embrella Cardiovascular News

Shares of Edwards Lifesciences are among the biggest gainers on the Standard & Poor's 500 index today, boosted after the company announced a $750 million share buyback program .

Larry L. Wood, Edwards Lifesciences' Corporate Vice President, Transcatheter Heart Valves, is scheduled to speak to conference attendees at 10:00 a.m. PT .

The firm currently has a "neutral" rating on the stock. Other equities research analysts have also recently issued reports about the stock.

Several insiders made buys this week as the price of their companies hit or neared 52-week low prices.

A Form 4 filed with the SEC has disclosed that Wesley von Schack, a member of the Board of Directors at Edwards Lifesciences Corp , directly acquired 2,000 shares on April 26th at an average price of $64.95 per share.

The firm currently has a "sell" rating on the stock. A number of other firms have also recently commented on EW.

The firm currently has a "buy" rating on the stock. EW has been the subject of a number of other recent research reports.

Earlier this week the stock of Edwards Lifesciences tanked after the company announced weak Sapien sales and lowered its sales guidance for the rest of the year.

This week brought about several 52-week low prices in the technology sector of the market.

The firm currently has a "neutral" rating on the stock. Several other analysts have also recently commented on the stock.

's stock had its "neutral" rating reaffirmed by Zacks in a research note issued on Wednesday, AnalystRatings.Net reports.

Medtronic is not too far behind, although it has been hobbled by a slow-enrolling pivotal trial that finally closed in early January.

The technology leader in transcatheter heart valves seems to be stalling when it comes to product adoption - at least in the short term.

Edwards Lifesciences announced its earnings results on Tuesday. The company reported $0.72 earnings per share for the quarter, missing the analysts' consensus estimate of $0.76 by $0.04, StockRatingsNetwork reports.

Analysts project a profit of 76 cents a share, a rise from 53 cents per share a year ago.